• Vaccine Name: SARS Subunit Spike Protein with subunit boosting Vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Vaccine Ontology ID: VO_0011486
• Type: Recombinant vector vaccine
• Status: Research
• S protein gene of SARS-CoV gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001237
• Immunization Route: Subcutaneous injection

Mouse Response

• Host Strain: BALB/c (Du et al., 2008)
• Host age: 4-6 weeks (Du et al., 2008)
• Host gender: Female (Du et al., 2008)
• Vaccination Protocol: Mice were Mice were separated into 4 groups (9 mice per group) and primed with RBD-rAAV [intramuscular (i.m.), 2 × 10^11 VP /200 μl)] or RBD-peptides (N50 and N60, 50 μg each) plus CpG ODN (25 μg) [subcutaneous, (s.c.)] or blank AAV, and boosted with RBD-rAAV or RBD-Pep or AAV, respectively (Du et al., 2008).
• Immune Response: Vaccination increased production (P < 0.05) of IL-4-producting Th2 cells higher than those in RBD-rAAV prime/RBD-rAAV vaccinated animals, but a lower level (P < 0.05) of IL-10-secreting Th2 cells that play roles in down-regulation of immune responses, as compared to those of RBD-rAAV prime/RBD-rAAV boost vaccination. RBD-rAAV prime/RBD-pep exhibited similar frequencies of IFN-γ-producing cells (Th1) to RBD-rAAV prime/RBD-rAAV boost vaccinated animals. Increased production of IL-2-secreting cells. Induction of SARS-CoV-specific IgG production. (Du et al., 2008)
• Challenge Protocol: Mice intranasally challenged with SARS-CoV strain GZ50 40 days post-vaccination (Du et al., 2008).
• Efficacy: SARS-CoV viral load in lung tissues was significantly reduced in mice vaccinated with RBD-Pep. Very low level of viral load was detected in lung tissues of RBD-rAAV prime/RBD-Pep boost group, similar to that in lung tissues of RBD-rAAV prime/RBD-rAAV boost group. Vaccination of RBD-rAAV prime/RBD-peptide boost was able to significantly inhibit SARS-CoV infection (Du et al., 2008).